Skip to main content

Sialorrhea

6
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
5
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Supernus Pharmaceuticals
3 programs
3
MYOBLOCPhase 3
MYOBLOCPhase 3
MYOBLOC Low DosePhase 31 trial
Active Trials
NCT05097079Withdrawn0Est. May 2023
US WorldMeds
US WorldMedsKY - Louisville
2 programs
2
MYOBLOCPhase 31 trial
MYOBLOCPhase 31 trial
Active Trials
NCT02610868Completed187Est. Jun 2017
NCT01994109Completed187Est. Jan 2017
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
BOTULINUM NEUROTOXIN TYPE-APhase 2/31 trial
Active Trials
NCT01489904Unknown60Est. Nov 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Supernus PharmaceuticalsMYOBLOC Low Dose
US WorldMedsMYOBLOC
US WorldMedsMYOBLOC
AbbVieBOTULINUM NEUROTOXIN TYPE-A

Clinical Trials (4)

Total enrollment: 434 patients across 4 trials

NCT05097079Supernus PharmaceuticalsMYOBLOC Low Dose

Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects

Start: Nov 2021Est. completion: May 20230
Phase 3Withdrawn
NCT02610868US WorldMedsMYOBLOC

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

Start: Oct 2015Est. completion: Jun 2017187 patients
Phase 3Completed
NCT01994109US WorldMedsMYOBLOC

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

Start: Nov 2013Est. completion: Jan 2017187 patients
Phase 3Completed
NCT01489904AbbVieBOTULINUM NEUROTOXIN TYPE-A

Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy

Start: Nov 2011Est. completion: Nov 201260 patients
Phase 2/3Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.